Core Insights - Kolon Biotech and Crescent Biopharma have established a strategic partnership, with Kolon granting Crescent rights to its ADC drug SKB105 outside of China, potentially generating over $1.3 billion in licensing revenue [2][3] - The collaboration includes the development of single-agent therapies for both SKB105 and Crescent's PD-1/VEGF bispecific antibody CR-001, as well as evaluating the combination therapy of CR-001 with SKB105 [2][3] Company Summaries - Kolon Biotech will receive an upfront payment of $80 million from Crescent, with eligibility for up to $1.25 billion in milestone payments and tiered royalties based on SKB105's net sales [3] - Crescent will pay Kolon an upfront fee of $20 million, with potential milestone payments of $30 million and tiered royalties based on CR-001's net sales [3] Industry Context - The partnership enhances Kolon Biotech's differentiated oncology pipeline and supports the global development of SKB105 [4] - The PD-1/VEGF bispecific antibody market is a hot area for development, with Chinese companies leading in progress and efficacy, attracting interest from multinational pharmaceutical companies [5] - The combination of ADCs with PD-1/VEGF bispecific antibodies is becoming a clear technical direction in the pharmaceutical industry, as evidenced by other collaborations in the sector [5]
ADC药物与PD-1/VEGF双抗联用再添案例 科伦博泰与Crescent达成双向授权协议